Drug
Eslicarbazepine clinical trials
Also written BIA 2-093, Zebinix, Aptiom and SEP-0002093.
A product of Eslicarbazepine; its studies count on that page too.
- studies test it
- 57
- open now
- 0
- in phase 3
- 14
- first study started
- 2000
How studies write it
Studies that test it under each name
Name
- ESL
- 9
Development codes
Studies by the year they started
57 studies that test it; most in 2007 (10)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 10 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 7 |
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 31
- Phase 2
- 11
- Phase 3
- 14
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Epilepsy
- 35
Who runs them
Industry 57 · Other 0
Bial - Portela C S.A. (51) · Sumitomo Pharma America, Inc. (5) · Whanin Pharmaceutical Company (1)
Often tested with
Tested in the same studies.
Oxcarbazepine (3) · Topiramate (1) · Moxifloxacin (1) · Simvastatin (1) · Carbamazepine (1) · Phenytoin (1) · Warfarin (1) · Lamotrigine (1)
Studies
Open first, then newest update. How each study uses eslicarbazepine is read from its arms, and is right about nine times in ten.
Testing it · 57
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateCompletedPhase 1Bial - Portela C S.A.NCT02283814Written as BIA 2-093
- Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac RepolarizationCompletedPhase 1Bial - Portela C S.A.NCT02283788Written as BIA 2-093
- Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepineCompletedPhase 1Bial - Portela C S.A.NCT02281591Written as BIA 2-093
- A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT01879345Written as BIA 2-093 - 1800 mg (Group 1)
- The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of DigoxinCompletedPhase 1Bial - Portela C S.A.NCT02172742Written as BIA 2-093
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT01679002Written as BIA 2-093
- Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyCompletedPhase 3Bial - Portela C S.A.NCT00957047Written as eslicarbazepine acetate
- Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresCompletedPhase 3Bial - Portela C S.A.NCT00957684Written as eslicarbazepine acetate
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCompletedPhase 3Bial - Portela C S.A.NCT00988429Written as 800 mg QD Eslicarbazepine acetate
- A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset SeizuresCompletedPhase 4Sumitomo Pharma America, Inc.NCT03116828Written as Eslicarbazepine acetate
- Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian AdultCompletedPhase 1Whanin Pharmaceutical CompanyNCT04095182Written as Zebinix 400mg
- Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenCompletedPhase 3Bial - Portela C S.A.NCT00988156Written as Eslicarbazepine acetate (BIA 2-093)
- Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset SeizuresCompletedPhase 3Bial - Portela C S.A.NCT02484001Written as ESL 800 mg
- Eslicarbazepine Acetate Monotherapy Long Term StudyCompletedPhase 3Sumitomo Pharma America, Inc.NCT00910247Written as Eslicarbazepine acetate
- A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the DrugWithdrawnPhase 3Sumitomo Pharma America, Inc.NCT03108729Written as Eslicarbazepine acetate
- Pharmacokinetics, Efficacy and Tolerability of BIA 2-093CompletedPhase 2Bial - Portela C S.A.NCT02170064Written as BIA 2-093 (Eslicarbazepine acetate)
- A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093CompletedPhase 2Bial - Portela C S.A.NCT02170077Written as BIA 2-093
- Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly PatientsCompletedPhase 3Bial - Portela C S.A.NCT01422720Written as Eslicarbazepine Acetate
- Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its MetabolitesCompletedPhase 1Bial - Portela C S.A.NCT02172755Written as BIA 2-093
- The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093CompletedPhase 1Bial - Portela C S.A.NCT02170649Written as BIA 2-093
See all 57 studies that test eslicarbazepine →
Given in every arm · 1 — eslicarbazepine is usual care beside what is tested
Codes
What other systems call eslicarbazepine · ClinicalTrials.gg INT004288
- MeSH (NLM) C416835eslicarbazepine acetateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BEA68ZVB2KESLICARBAZEPINE ACETATEConfirmed FDA, NLM, Wikidata
- RxNorm 1482501Confirmed FDA, Wikidata
- Wikidata Q410273eslicarbazepine acetateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83697Eslicarbazepine AcetateOne source FDA
- DrugBank DB09119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C416835 | eslicarbazepine acetate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BEA68ZVB2K | ESLICARBAZEPINE ACETATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1482501 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410273 | eslicarbazepine acetate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83697 | Eslicarbazepine Acetate | One source FDA |
| DrugBank | DB09119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.